Diplomat Specialty Pharmacy expands to Southern California
SWARTZ CREEK, Mich. Diplomat Specialty Pharmacy last week announced the opening of its branch in San Bernardino, Calif.
Diplomat has six additional locations in Michigan, Ohio, Illinois and Florida.
“In January, our contracts with managed care organizations in California will potentially impact over 1 million people,” stated Atheer Kaddis, Diplomat’s VP managed care. “Our new San Bernardino location is an important resource for those patients. It will also provide our customers in the Western United States with best-in-class distribution and patient care services.”
“With new West Coast managed care contracts and expanded national programs we are thrilled to be adding a location in the greater Los Angeles area,” stated Phil Hagerman, president and CEO of Diplomat Specialty Pharmacy. “We also look forward to providing new jobs in southern California as we build out our facility to be a full service West Coast distribution center for Diplomat.”
GSK withdraws regulatory application for additional use of Avodart
LONDON British drug maker GlaxoSmithKline is temporarily withdrawing its regulatory approval application seeking an additional use for an enlarged prostate treatment in order to update it, the company announced Monday.
The company is seeking approval from the Food and Drug Administration of Avodart (dutasteride) for prostate cancer risk reduction in men who have increased risk of developing the disease. The drug is currently approved for treating enlarged prostate.
GSK did not specify what it would add to the application, but said the updates were not related to new safety or efficacy findings and that it would resubmit the application “shortly.”
Save Flexible Spending Plans lobbying FSA reform
NEW YORK The simple fact is that healthcare reform in this country has to be paid for somehow. But cutting OTCs out of FSAs amounts to an additional healthcare tax levied against Americans actually trying to save money on health care today. That’s just backward thinking.
When you consider that allowing thrifty Americans to buy an OTC allergy medication with pre-tax funds may dissuade them from buying a generic Rx-only allergy medication for the cheaper co-pay. And while those Rx-allergy users are taking care of their generic co-pay, who’s picking up on the cost of the rest of the medicine?
Approximately 14.8% of American households have an FSA account, according to the National Center for Health Statistics, which means that some 16.5 million families are saving pre-tax income dollars. The Senate shouldn’t be looking to cut this healthcare savings a la tax benefit; they should be trying to figure out how to get more Americans turned onto FSA savings.